Corcept’s Research & Development Program
Evidence in the scientific literature suggests that competitive blockade of one of the body’s two glucocorticoid receptors (GR) may have utility in treating a wide range of conditions, including Cushing’s syndrome, psychotic depression, anti-psychotic drug induced weight gain, diabetes, obesity, hypertension, Alzheimer’s disease, post-traumatic stress disorder, alcoholism, breast and ovarian cancer.
Corcept is the leading company investigating the potential therapeutic benefit of competitive GR blockade. Mifepristone, the active ingredient in our marketed product, blocks GR and the progesterone receptors. We have now developed a library of more than 300 next-generation compounds that competitively block only GR, and have begun advancing several of these compounds toward human use.
Prolonged exposure to high levels of cortisol adversely affects multiple systems throughout the body
Cushing's syndrome is an endocrine disorder caused by prolonged exposure to high levels of cortisol. Patients with Cushing's syndrome have multiple symptoms which may include high blood sugar, diabetes, high blood pressure, upper body obesity, rounded face, increased fat around the neck, thinning arms and legs, severe fatigue and weak muscles. Irritability, anxiety, cognitive disturbances and depression are also common. Cushing's syndrome can affect every organ system in the body and can be lethal if not treated effectively and early. Blocking the glucocorticoid receptor can have significant results in many of these patients.